Baltic Countries

ScanBalt celebrates its 10th anniversary

17.08.2011

Under the motto “10 Years ScanBalt Bioregion – Towards a Balanced Regional Development and Smart Specialisation in the Baltic Sea Region”, the ScanBalt Bio­Region is holding the 10th ScanBalt Forum from September 21st-23rd. Launched in 2001, ScanBalt has become the most significant cooperation network for the life sciences and health sector in Northern Europe. The cross-border initiative that is headquartered in Copenhagen encompasses a region of 85 million inhabitants, 60 universities, 248 hospitals and about 2,500 life science and biotech com­panies – around 700 of which are SMEs.

The key issue for ScanBalt is to bundle the interests of its 67 members in the Baltic Sea Region, as well as North-West Russia, Norway and the Northern Netherlands. And the network is accomplishing that task with increasing success. So far, 15 international projects for companies, universities, and research facilities have been initiated and supported under the ScanBalt umbrella, all of them aimed at developing the areas bordering the Baltic Sea into a globally competitive meta-region. Taking yearly turns, members rotate duties in the ScanBalt Forum in order to strengthen cross-border cooperation within the ScanBalt Bio region. Following the founding session at the first Baltic Biotech Forum, which took place in Teschow in the German State of Mecklenburg-Vorpommern in 2001, the event has migrated almost completely around the Baltic Sea region from Oslo to Tallinn. The meeting in Heringsdorf on the German/Polish island of Usedom marks the return of ScanBalt to the southernmost areas of the initiative.

Flagship for Europe:

the Baltic Sea Health Region

The agenda of this year’s Forum is filled with topics like the EU flagship “Baltic Sea Health Region” project, the “Green Valley”project with environmental projects and activities in the region, and the opportunities and challenges of cross-border cooperation in the Baltic Sea Region. Contributors to the 2010 ScanBalt Forum in Tallin (Estonia) successfully managed to incorporate the “ScanBalt Health Region” project as a keystone in the EU Baltic Sea Strategy, and added proposals to the emerging 8th EU Research Framework Programme, which includes a “Master Plan on Health“ for the Baltic Sea region.
Successes like these have encouraged the 2011 Forum organisers. ScanBalt chairman Wolfgang Blank has high expectations: “The ScanBalt BioRegion has emerged as a model region for Europe in the cooperation between business, universities, and the public sector. In future, we need to keep working to improve the mobility of people, know­ledge, and ideas within Europe, and to reduce regional inequalities. In Heringsdorf, we are attempting to pave the way for well-balanced regional development.”

Cross-border success

Lectures and workshops are one way to present new projects from areas that include ­regenerative medicine, marine and industrial biotechnology, the fight against multi-resistant bacteria, identifying and defining new areas of cooperation, developing expansion strategies in the life sciences and health economy fields, and for mobilising resources for implementation. 250 participants from business, science, and the public sector are expected at the Forum, which falls under the patronage of Mecklenburg-Vorpommern, currently led by state premiere Erwin Sellering. Anyone interested is welcome to attend (registration at: www.scanbaltforum2011.eu).
The ScanBalt Forum is organised by the West Pomeranian Medical University Szczecin/Poland, the University of Klaipeda/Lithuania and as part of the project Eco4­Life, which is partly financed by the EU (European Regional Development Fund). The lead partner is BioCon Valley® GmbH, a central contact and service provider for life sciences, biotechnology and the bio­sciences in Mecklenburg-Vorpommern.

Baltic Countries

13.05.2010

Riga – Latvian producer of active pharmaceuticals ingredients Grindeks has baggedEUR4.1m in funding from the European Regional Development Fund to build a new 1,400 m2 plant for the production of ursodeoxycholic acid (UDCA). The...

Baltic Countries

12.05.2010

Kaunas/Martin – Lithuania’s largest pharmaceutical manufacturer Sanitas AB transferred its ownership in Slovakia’s HBM Pharma sro to the Lat­vian company SIA Liplats 2000 at the end of April. The companies have agreed to transfer...

Baltic Countries

18.08.2008

Riga – Starting in June, Lithuanian researchers involved in FP7 funding projects have the possibility to receive national co-funding if the EU funding programme does not cover 100% of the project cost. Additionally, a new grant...

Baltic Countries

20.05.2008

Riga – Pharmaceutical manufacturer Grindeks is continuing to expand. After opening a representative office in Uzbekistan, the company has now signed an agreement with Wake Forest University’s School of Medicine (US) to supply...

Baltic Countries

19.03.2008

Riga – The Latvian Government will be funding a EUR6 million vaccination programme over the next three years. The programme will cover vaccinations against tuberculosis, hepatitis B, tetanus, tick encephalitis, influenza, polio,...

Baltic Countries

19.02.2008

Vilnius/Brussels – For the first time, the European Commission has taken a member state of the European Union to the European Court of Justice because it refuses to take a biosimilar from the market. Lithuania has refused to...

Baltic Countries

22.11.2007

Riga – Latvia’s largest pharmaceutical manufacturer, JSC Grindeks, has signed a letter of intent (LOI) with two pharmaceutical companies in Belarus during the third meeting of the “Latvian-Byelorussian Inter-Governmental...

Baltic Countries

24.09.2007

Riga – JSC Grindeks has improved its half-year result in 2007. In the first six months of this year, the company‘s revenues grew by 25% to €37.1 million. Half of Grindeks made most sales in Russia (€18.8 million, +8%), and other...

Baltic Countries

11.07.2007

Kaunas – Sanitas AB group net profits have risen by almost seven times (598%) to a6.2 million in the first quarter of 2007 compared to last year, the Lithuanian pharmaceutical manufacturer reported at the end of May. Turnover...

Baltic Countries

11.07.2007

Riga – In mid June, LSC Grindeks unveiled a new a4.5 million cGMP and GLP compliant laboratory for scale-up procedures and industrial analytics – the only lab of this kind in the Baltic States, says the company. “The development...

Displaying results 11 to 20 out of 58

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-baltic-countries/browse/1/article/scanbalt-celebrates-its-10th-anniversary.html

Events

All Events

Stock list

All quotes

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-26.8%
  • PROSENSA (NL)9.48 USD-25.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • PROSENSA (NL)9.48 USD-68.0%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products